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and TEC family kinases (TEC and BTK). The Src family kinases are involved in T cell activation, signal transductions, 60 blocking cell duplications, adhesion et al [6] . Dasatinib potently inhibits Src family kinases, diminishing metastatic spread 61 the side effects of dasatinib. Collectively, our results reveal a group of dasatinib-targets, demonstrating the potential dasatinib 90 mechanism on inhibition of T cell activation and proliferation. Deciphering dasatinib molecular basis is significantly benefit 91 to patients with diseases, such as autoimmune, GVHD, transplant rejection, and CML. These data extend our knowledge 92 regarding the dasatinib molecular mechanism.
94

Results
95
CRISPR/Cas9 Screening with a custom library
96
To identify the dasatinib targets with CRISPR/Cas9 screen, we designed and synthesized a custom CRISPR/Cas9 library. 
103
These 6,149 genes were involved in several important KEGG pathways, including ribosome, cell cycle, pathways in cancer, 104 CML, AML, and et al (Fig 1b) . All sgRNAs were synthesized and cloned into a lentivirus library that was then infected into 105 cells at a low multiplicity of infection to ensure each cell takes up only one sgRNA as possible (Fig 1a) . The concentration 106 of dasatinib treatment was identified with the half maximal inhibitory concentration (IC50) experiments (Fig 1c) . The IC50 107 of dasatinib was 300 nano-molar in jurkat cells. SgRNAs that were incorporated into the host genome can be replicated with 108 the host cell division. These virally infected cells were selected and split into 3 populations at a starting time point. One 109 population representing the initial sgRNA status (day0) was harvested for sequencing. The remaining 2 populations were 110 respectively treated with dasatinib (treatment) and vehicle (control) and allowed to grow under same experimental conditions 111 for 10 double time (~4 weeks). The screening operations were conducted in parallel to minimize the technical variations. At 112 the end of the screen, genomic DNA from the infected cells was extracted and the sgRNA-encoded regions that viruses had 113 integrated to host genome were sequenced using single-end Illumina platform. 43.67 million reads were generated in the 3 114 samples in total. The read count of each sgRNA was a proxy for the cell growth characteristics under a knockout of the gene 115 targeted by the sgRNA.
117
The sequencing data were analyzed using the MAGeCK (v0.5.7) package[14] that uses negative binomial distribution to 118 calculate beta score, which represents CRISPR screening performance on each genes. The beta score is similar to the log2-119 transferred fold-change in gene differential expression analysis. By comparing dasatinib-treated and vehicle-treated sample 120 to day0 sample, we obtained treatment and control beta score (CBS), respectively. Dasatinib-targeting genes were identified 121 on the basis of comparison of treatment beta scores (TBS) to CBS. Mapping these sequencing reads onto the CRISPR library,
122
we found that at least 85% sgRNAs were sequenced with more than or equal 53 reads in the 3 samples (Fig 1d) 
130
We firstly identified essential genes for Jurkat cell survival. Identification of essential genes can enable us to understand T 131 cell proliferation. By comparing the control sample to day0, we calculated CBS. Using 1-quantile standard deviation (QSD) 132 as cutoff, we identified 238 positively selected genes (PSGs) with beta scores greater than the cutoff, indicating these gene 133 could suppress T-cell proliferation (Fig 2a and Supplementary table 1) . We also identified 1,714 negatively selected genes 134 (NSGs) with beta scores less than the cutoff (Fig 2a and Supplementary table 1) , indicating these genes are required for T-135 cell proliferation. As expected, these NSGs were enriched in ribosome, spliceosome, RNA transport, and cell cycle pathways 
149
PSGs across at least more than 20 cell lines at a cutoff of 1 QSD (Fig 2b) , suggesting that these genes were selected from the 150 majority of cell lines. Thus, we defined these genes as common positively and common negatively selected genes. Excluding 
159
GO term and KEGG pathway enrichment analysis, we found that these negative Jurkat-specific selected genes were 160 pertaining to such pathways as fanconi anemia pathway, alcoholism, and et al (SFig 2f, g ). Visualizing control beta scores 161 onto fanconi anemia pathway, we found almost all screened genes, excepting PMS2, were negative selected, indicating these 
167
To identify dasatinib-targeting genes, we identified treatment beta scores (TBS) by comparing dasatinib-treated library to 168 day0, and then comparing TBS to CBS. We identified a list of beta score differences between TBS and CBS, which reflects 
173
(CASP8 and FADD like apoptosis regulator), were positively selected. This suggests that the genes more essential in control 174 cells than in dasatinib-treated cells (Fig 3b) , indicating that these genes as cell fitness genes whose functions were inhibited 175 by dasatinib treatment. Thus, these genes are potential targets of dasatinib. CSK and LCK as tyrosine kinases, were previously 176 known to be dasatinib targets [16] . By contrast, the bottom 5 genes: SIK3 (SIK Family Kinase 3), CDK6 (cyclin dependent 177 kinase 6), BCL2L1 (BCL2 like 1), KMT2C (lysine methyltransferase 2C), and TONSL (tonsoku like, DNA repair protein), 178 were negatively selected. This suggests that these genes were more essential in dasatinib-treated cells than in control cells 179 (Fig 3b) , indicating that the loss of these genes sensitized the cells to dasatinib. Therefore, these genes when inhibited would 180 synergistically enhance dasatinib treatment for T cells. Examining the sgRNA changes between the 3 samples, we found that 181 sgRNAs of LCK, CSK, and CFLAR in dasatinib-treated sample were higher than in control sample, supporting positive 182 selection by dasatinib, while SIK3 and CDK6 in treatment were lower than in control, supporting negative selection by 183 dasatinib (Fig 3c) . We performed KEGG pathway enrichment analysis for the bottom 400 negatively selected genes and 184 found these genes were significantly enriched in chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and 185 TGF-beta signaling pathways, suggesting that dasatinib treatment is implicated in the alterations on these pathways (SFig 186 3b), thus potentially improving the pathology of CML and AML. Performing GSEA analysis, we found many genes in CML 187 and AML pathways were negatively selected (SFig 3d, e, g, h), indicating that CML and AML pathways were suppressed 188 when cells were treated with dasatinib, which supports the therapy of dasatinib in CML and AML patients. More importantly, 189 we found 13 positively and 13 negatively selected genes in TCR signaling pathway at cutoff of 1-QSD (Fig 3d) 
205
To further explore dasatinib molecular function, we assigned all genes into 9 squares using 1-QSD as a cutoff for CBS 206 and TBS (Fig 4a) . The delta score (TBS-CBS) reflects dasatinib treatment. Genes selected by CBS were associated with cell 207 growth, while genes selected in TBS were associated with both dasatinib treatment and cell growth. We highlighted 4 groups: indicating genes in group A may be associated with dasatinib resistance, while in group C, cell grew lower than control, 214 indicating may be associated with dasatinib response. Ranking the beta score difference, the top 5 genes in group A are 215 NUDCD1, CST4, DLX5, SIGMAR1, and NLRP7, and bottom 5 genes in group C are SIK3, KMT2C, RPL41, SLC25A22, 216 and PRKDC. We performed GO biological process and KEGG pathway enrichment analysis for group A and C (Fig 4b, c) .
217
The top 10 enriched KEGG pathways includes Hedgehog signaling pathway, long-term potentiation, and cholesterol 218 metabolism pathway, and top 10 GO biological processes includes regulation of cell fate commitment, which are consistent 219 with previous studies [18, 19] . Similarly, group B were less positive selection after dasatinib treatment than control, 220 suggesting these genes may be synergy effect with dasatinib, while group D were less essential after dasatinib treatment than 221 control, indicating these genes may be dasatinib targets. We performed enrichment analysis for group B and D as well, 222 indicating that these genes were pertaining into pathways, including systemic lupus erythematosus, viral carcinogenesis, 
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Token gather, the Jurkat-specific selected genes will benefit to the community for understanding the T cell characteristics. 
267
Fourth, assigning all genes into 9-square with a cutoff of 1-QSD, we identified 4 group genes. Genes positively and negatively 268 selected in dasatinib treatment but not in control may be associated dasatinib resistance and response. These genes are 269 associated with systemic lupus erythematosus, viral carcinogenesis, alcoholism, Th17 cell differentiation, Th1 and Th2 cell 270 differentiation pathways. Clinical evidences shown that patients with long term treatment of dasatinib may suffer severe side 271 effects, including system lupus erythematosus, alcoholism, and immune suppression [22] . These data suggest that these genes 272 may be associated with dasatinib side effects.
274
Finally, while we believe that these identified genes are important for T cell survival and dasatinib treatment, some issues 275 remain to be addressed. We used Jurkat cells as model, which is different from Ph+ CML cells. The screen library covers 276 6149 genes only. it is possibly missing some important genes. Although these limitations are existing in the data, these data 277 are largely extending our understanding to dasatinib mechanism, which will facilitate an improvement on dasatinib treatment 278 in clinic. Overall, although our study has certain limitations, because of the cell line in the experiments, requiring additional 279 validations, we nonetheless identified a group of T cell essential genes and found that dasatinib-treatment is closely associated 280 with CML and AML pathways. These findings refine our understanding to T cell proliferation, and dasatinib mechanism, 281 which will facilitate the advantage in the clinic outcome.
283
Conclusions
284
Immune response by T cell activation and expansion is of importance to the body against cancer-antigens, pathogen-, antigens, 285 and self-peptides. if over activation or proliferation of T cell, the immune system could fail to protect and even attack the 286 body with diseases, such as autoimmune disease and GVHD. We have presented CRISPR screens with dasatinib-treatment 287 in T cells. We identified a set of essential genes for T cell survival, which will contribute to the field with extending the 288 understanding of T cell survival mechanism. With dasatinib treatment, we identify dasatinib targets and demonstrating the 
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MAGeCK-VISPR models the gRNA read counts as a negative binormal variable, which mean value is determined by the 347 sequencing depth of the sample, the efficiency of the gRNA, and a linear combination of β scores of the genes. MAGeCK-
348
VISPR builds a maximum likelihood (MLE) model to model all gRNA read counts of all samples, and iteratively estimate 349 the gRNA efficiency and gene β scores using the Expectation-Maximization (EM) algorithm. A detailed description of the
350
MAGeCK-MLE algorithm can be found in the original study [14] .
351
We identified Jurkat essential genes by control sample compared with starting time sample, using MAGeCK, and 
